[1]初晓玲,吴 波,蓝晓红,等.胶质母细胞瘤耐药性基因筛选及治疗药物预测[J].医学信息,2024,37(19):10-18.[doi:10.3969/j.issn.1006-1959.2024.19.002]
 CHU Xiaoling,WU Bo,LAN Xiaohong,et al.Drug Resistance Gene Screening and Therapeutic Drug Prediction of Glioblastoma[J].Journal of Medical Information,2024,37(19):10-18.[doi:10.3969/j.issn.1006-1959.2024.19.002]
点击复制

胶质母细胞瘤耐药性基因筛选及治疗药物预测()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年19期
页码:
10-18
栏目:
生物信息学
出版日期:
2024-10-01

文章信息/Info

Title:
Drug Resistance Gene Screening and Therapeutic Drug Prediction of Glioblastoma
文章编号:
1006-1959(2024)19-0010-09
作者:
初晓玲1吴 波1蓝晓红1易剑峰2李薛梅1陈旭青1
1.东部战区总医院药剂科,江苏 南京 210002;2.江西中医药大学中医基础理论分化发展研究中心,江西 南昌 330004
Author(s):
CHU Xiaoling1WU Bo1LAN Xiaohong1YI Jianfeng2LI Xuemei1CHEN Xuqing1
1.Department of Pharmacy,Eastern Theater Command General Hospital,Nanjing 210002,Jiangsu,China;2.Research Center for Differentiation and Development of Basic Theories of TCM,Jiangxi University of Traditional Chinese Medicine,Nanchang 330004,Jiangxi,China
关键词:
胶质母细胞瘤替莫唑胺耐药基因生物信息学中药预测
Keywords:
GlioblastomaTemozolomideDrug resistance genesBioinformaticsTraditional Chinese medicine prediction
分类号:
R969
DOI:
10.3969/j.issn.1006-1959.2024.19.002
文献标志码:
A
摘要:
目的 运用生物信息学技术筛选胶质母细胞替莫唑胺(GBM TMZ)耐药差异表达基因(DEGs),探寻关键耐药基因及发病机制,并预测相关作用中药。方法 在GBM、GEO2R和GPEIA等多种数据库基础上进行生物学功能及通路富集分析,构建蛋白互作网络筛选关键基因,检索关键基因在正常人、胶质瘤患者组织中mRNA表达及生存率的影响。利用COREMINE平台对关键耐药基因构建药物-活性成分-作用靶点网络,筛选相关中药活性成分。结果 共筛选出293个DEGs,涉及FN1、CD44、CTGF、FOS等关键靶点,其表达显著高于正常人,影响患者总生存率,是GBM有害预后因素,但不会影响无复发生存率。影响细胞粘附、神经系统发育、转化生长因子β受体信号传导和基因正向调节等生物学功能。经COREMINE预测发现,与FN1关系密切的干预药物多归属肝经,性味多以清热类和补虚类为主。结论 筛选出12个与GBM TMZ耐药相关的关键基因,FN1在TMZ耐药发生发展中起重要作用,木香、青叶胆及蓖麻子的活性成分可能作为TMZ耐药治疗药物来源。
Abstract:
Objective To screen differentially expressed genes (DEGs) of temozolomide (TMZ) resistance in glioblastoma cells (GBM) by bioinformatics technology, explore the key drug resistance genes and pathogenesis, and predict the related traditional Chinese medicine.Methods Based on GBM, GEO2R, GPEIA and other databases, biological function and pathway enrichment analysis were carried out, and protein interaction network was constructed to screen key genes. The effects of key genes on mRNA expression and survival rate in normal human and glioma patients were searched. The COREMINE platform was further used to construct a drug-active ingredient-target network for key drug resistance genes, and the active ingredients of related Chinese medicines were screened.Results A total of 293 DEGs were screened, involving key targets such as FN1, CD44, CTGF, and FOS. The expression was significantly higher than that of normal people, affecting the overall survival rate of patients, and was a harmful prognostic factor for GBM, but it did not affect the recurrence-free survival rate. While it affected biological functions such as cell adhesion, nervous system development, transforming growth factor β receptor signal transduction and gene positive regulation. It was predicted by COREMINE that the intervention drugs closely related to FN1 were mostly attributed to the liver meridian, and the nature and flavor were mainly heat-clearing and deficiency-tonifying.Conclusion Twelve key genes related to TMZ resistance in GBM were screened out. FN1 plays an important role in the occurrence and development of TMZ resistance. The active components of Muxiang, Qingyedan and Bimazi may be used as the source of TMZ resistance drugs.

参考文献/References:

[1]Ostrom QT,Gittleman H,Truitt G,et al.CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015[J].Neuro Oncol,2018,20(suppl_4):1-86.[2]Verdugo E,Puerto I,Medina M?譧.An update on the molecular biology of glioblastoma, with clinical implications and progress in its treatment[J].Cancer Commun,2022,42(11):1083-1111.[3]Wu L,Wu W,Zhang J,et al.Natural Coevolution of Tumor and Immunoenvironment in Glioblastoma[J].Cancer Discov,2022,12(12):2820-2837.[4]国家卫生健康委员会医政医管局,中国抗癌协会脑胶质瘤专业委员会,中国医师协会脑胶质瘤专业委员会.脑胶质瘤诊疗指南(2022版)[J].中华神经外科杂志,2022,38(8):757-777.[5]Delello Di Filippo L,Hofst?覿tter Azambuja J,Paes Dutra JA,et al.Improving temozolomide biopharmaceutical properties in glioblastoma multiforme (GBM) treatment using GBM-targeting nanocarriers[J].Eur J Pharm Biopharm,2021,168:76-89.[6]Campos-Sandoval JA,Gómez-García MC,Santos-Jiménez JL,et al.Antioxidant responses related to temozolomide resistance in glioblastoma[J].Neurochem Int,2021,149:105136.[7]Sui Y,Li S,Fu XQ,et al.Bioinformatics analyses of combined databases identify shared differentially expressed genes in cancer and autoimmune disease[J].J Transl Med,2023,21(1):109.[8]Zhang H,Xia P,Liu J,et al.ATIC inhibits autophagy in hepatocellular cancer through the AKT/FOXO3 pathway and serves as a prognostic signature for modeling patient survival[J].Int J Biol Sci,2021,17(15):4442-4458.[9]Sharma MK,Srivastav VK,Joshi CK,et al.Annotated protein network analysis linking oral diseases[J].Bioinformation,2022,18(8):724-729.[10]Xie R,Li B,Jia L,et al.Identification of Core Genes and Pathways in Melanoma Metastasis via Bioinformatics Analysis[J].Int J Mol Sci,2022,23(2):794.[11]Nie E,Jin X,Miao F,et al.TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT[J].Neuro Oncol,2021,23(3):435-446.[12]Gao Z,Xu J,Fan Y,et al.PDIA3P1 promotes Temozolomide resistance in glioblastoma by inhibiting C/EBPβ degradation to facilitate proneural-to-mesenchymal transition[J].J Exp Clin Cancer Res,2022,41(1):223.[13]Yu X,Zhou Z,Tang S,et al.MDK induces temozolomide resistance in glioblastoma by promoting cancer stem-like properties[J].Am J Cancer Res,2022,12(10):4825-4839.[14]Yu Q,Xiao W,Sun S,et al.Extracellular Matrix Proteins Confer Cell Adhesion-Mediated Drug Resistance Through Integrin α v in Glioblastoma Cells[J].Front Cell Dev Biol,2021,9:616580.[15]Mala U,Baral TK,Somasundaram K.Integrative analysis of cell adhesion molecules in glioblastoma identified prostaglandin F2 receptor inhibitor (PTGFRN) as an essential gene[J].BMC Cancer,2022,22(1):642.[16]Song J,Zhao D,Sun G,et al.PTPRM methylation induced by FN1 promotes the development of glioblastoma by activating STAT3 signalling[J].Pharm Biol,2021,59(1):904-911.[17]Wu S,Liu C,Wei X,et al.High Expression of Fibronectin 1 Predicts a Poor Prognosis in Glioblastoma[J].Curr Med Sci,2022,42(5):1055-1065.[18]Song ZB,Yang HP,Xu AQ,et al.Connective tissue growth factor as an unfavorable prognostic marker promotes the proliferation, migration, and invasion of gliomas[J].Chin Med J (Engl),2020,133(6):670-678.[19]Knudsen AM,Eilertsen I,Kielland S,et al.Expression and prognostic value of the transcription factors EGR1 and EGR3 in gliomas[J].Sci Rep,2020,10(1):9285.[20]Chen L,Liu YC,Zheng YY,et al.Furanodienone overcomes temozolomide resistance in glioblastoma through the downregulation of CSPG4-Akt-ERK signalling by inhibiting EGR1-dependent transcription[J].Phytother Res,2019,33(6):1736-1747.[21]Siebzehnrubl FA,Silver DJ,Tugertimur B,et al.The ZEB1 pathway links glioblastoma initiation, invasion and chemoresistance[J].EMBO Mol Med,2013,5(8):1196-1212.

相似文献/References:

[1]王春城.放疗联合替莫唑胺在高级别脑胶质瘤患者中的疗效观察[J].医学信息,2019,32(03):160.[doi:10.3969/j.issn.1006-1959.2019.03.053]
 WANG Chun-cheng.Therapeutic Effect of Radiotherapy Combined with Temozolomide in Patients with High Grade Glioma[J].Journal of Medical Information,2019,32(19):160.[doi:10.3969/j.issn.1006-1959.2019.03.053]
[2]张伟斌,荆国杰.胶质母细胞瘤信号通路的研究[J].医学信息,2019,32(23):33.[doi:10.3969/j.issn.1006-1959.2019.23.009]
 ZHANG Wei-bin,JING Guo-jie.Study on Glioblastoma Signaling Pathway[J].Journal of Medical Information,2019,32(19):33.[doi:10.3969/j.issn.1006-1959.2019.23.009]
[3]王 京,王远传,梁若飞.TREM1在胶质母细胞瘤中的表达及其预后意义[J].医学信息,2021,34(09):69.[doi:10.3969/j.issn.1006-1959.2021.09.018]
 WANG Jing,WANG Yuan-chuan,LIANG Ruo-fei.The Expression of TREM1 in Glioblastoma and Its Prognostic Significance[J].Journal of Medical Information,2021,34(19):69.[doi:10.3969/j.issn.1006-1959.2021.09.018]

更新日期/Last Update: 1900-01-01